A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Inclusion Criteria

• Patients with histologically confirmed GBM and/or other glioma subtypes at the time of diagnosis or prior relapse.
• Written documentation of local or central laboratory determination of amplification or translocation to FGFR1-TACC1, FGFR3-TACC-3 fusion and/or activating mutation in FGFR1, FGFR2,or FGFR3
• RANO defined tumor progression by MRI in comparison to a prior scan
• Patients must have received prior external beam radiotherapy and temozolomide.

Exclusion Criteria

• History of another primary malignancy
• Prior or current treatment with a FGFR inhibitor
• Neurological symptoms related to underlying disease requiring increasing doses of corticosteroids
• Patients must not be taking Enzyme Inducing Anti-Epileptic Drug (EIAED). If previously on an EIAED, the patient must be off of it for at least two weeks prior to study treatment.